Trial Profile
Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs DA 9701 (Primary) ; Domperidone
- Indications Constipation; Dyspepsia
- Focus Therapeutic Use
- 05 Jun 2018 Primary endpoint (Change of gastric motility evaluated using MRI from baseline at 4 weeks after the treatment) has been met, according to results presented at the Digestive Disease Week 2018.
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018.
- 19 Jan 2017 New trial record